The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

J Hematol Oncol. 2024 Jan 4;17(1):1. doi: 10.1186/s13045-023-01509-2.


Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

Keywords: Antibody-drug conjugate; Combination therapy; Immunotherapy; Solid tumor; Targeted therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Immunoconjugates* / therapeutic use
  • Immunotherapy
  • Neoplasms* / drug therapy


  • Immunoconjugates
  • Antineoplastic Agents